Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has been approved by the Food and Drug Administration for ...

The U.S. Food and Drug Administration on Friday approved the first prescription medicine for obstructive sleep apnea: the ...

Eli Lilly stock rose Monday after Zepbound received Food and Drug Administration (FDA) approval as a treatment for obstructive sleep apnea among adults with obesity.

Zepbound, Eli Lilly’s weight loss drug, can now be used to treat obstructive sleep apnea in adults with obesity, the FDA said ...

The FDA said studies have shown that by aiding weight loss, Zepbound improves sleep apnea symptoms in some patients.

Dec 20 (Reuters) - The U.S. Food and Drug Administration on Friday approved Eli Lilly's (LLY.N), opens new tab weight-loss ...

The Food and Drug Administration today approved Eli Lilly’s weight-loss treatment, Zepbound, for obstructive sleep apnea, making it the first drug greenlighted to directly treat patients with the ...

Photo courtesy Eli Lilly & Co. Dec. 21 (UPI) --Zepbound, the new GLP-1 weight-loss drug from Eli Lilly ... pain to curbing asthma. Friday's FDA approval of Zepbound for treating moderate to ...

The Food and Drug ... weight-loss medications have garnered immense national attention and ignited a debate about access and demand for the drugs, which help people shave pounds. The FDA first ...

"The approval is the second indication for Zepbound, which was approved for weight loss ... the new FDA green light doesn't expand the number of people who may be eligible for the drug, since ...

Shelby Knowles/Bloomberg via Getty The weight loss drug Zepbound, generically known as tirzepatide, is also now an approved medication ... also supports the FDA’s new authorization.